Notch Therapeutics
Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.
Last updated on